ORPHA:618
Familial melanoma
Publications
1,514
Trials
1
Interventional, condition-specific
Researchers
1,423
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Familial melanoma (FM) is a rare inherited form of melanoma characterized by development of histologically confirmed melanoma in two first degree relatives or more relatives in an affected family.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018961
- UMLS:C1512419
- NCIT:C8498
Additional Mondo synonyms (1)
hereditary melanoma (disease)
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,514 matched papers (641 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
1 matched on ClinicalTrials.gov (1 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,514
1,514 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,514 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
641 in the last 10 years · low confidence
Phrase hits: 1,514 · MeSH hits: 0
Who's working on it?
1,423
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Puig S14 papers · 2023
Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Papers in Europe PMC - 02Soyer HP13 papers · 2025
Dermatology Research Centre, The University of Queensland Diamantina Institute, Brisbane, Australia.
Papers in Europe PMC - 03van Doorn R11 papers · 2026
Department of Dermatology, LUMC, Leiden, The Netherlands.
Papers in Europe PMC - 04Hayward NK10 papers · 2026
QIMR Berghofer Medical Research Institute, Herston, Australia.
Papers in Europe PMC - 05McInerney-Leo AM10 papers · 2024
Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT) at Translational Research Institute, Woolloongabba, Queensland, Australia.
Papers in Europe PMC - 06Adams DJ9 papers · 2026
Experimental Cancer Genetics Group, Wellcome Trust Sanger Institute, Hinxton, Cambridge, U.K.
Papers in Europe PMC - 07Goldstein AM9 papers · 2026
Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Papers in Europe PMC - 08Potrony M9 papers · 2023
Melanoma Unit, Dermatology Department, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Papers in Europe PMC - 09Höiom V8 papers · 2025
Department of Oncology Pathology, Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, Sweden.
Papers in Europe PMC - 10Tucker MA8 papers · 2026
Human Genetics Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; 1 currently recruiting in our sample. 2,889 trials are registered for melanoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
1 interventional trial — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 76.8th percentile).
low confidence · 76.8th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06767332·RECRUITING·EMDR for Fear of Cancer Recurrence in Patients with Familial Melanoma: a Waiting List Control Trial
Conditions: Familial Melanoma · Fear of Cancer Recurrence · Eye Movement Desensitization and Reprocessing · Psychological Intervention·Matched via name phrase
Broader category: melanoma
2,889
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07114172·NOT YET RECRUITING·Study of Melanoma-Resistant PET Monitoring Based on Key Rate-limiting Enzymes for Fatty Acid Metabolism in Healthy Volunteers
Conditions: Melanoma (Skin Cancer) · Health Volunteers · PET / CT·Matched via name phrase
- NCT07070518·RECRUITING·Study of GV20-0251 in Participants With Solid Tumor Malignancies
Conditions: Solid Tumor Cancer · Adult Refractory Cancer · Endometrial Carcinoma (EC) · Squamous Head and Neck Carcinoma·Matched via name phrase
- NCT05968690·RECRUITING·Naltrexone and Propranolol Combined With Immunotherapy
Conditions: Advanced Melanoma·Matched via name phrase
- NCT06545682·RECRUITING·Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
Conditions: Melanoma (Skin Cancer) · Breast Cancer · Brain Metastasases·Matched via name phrase
- NCT05955924·RECRUITING·Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
Conditions: Non-melanoma Skin Cancer · Carcinoma, Squamous Cell · Carcinoma, Basal Cell · Keratinocyte Carcinoma·Matched via name phrase
- NCT07459543·NOT YET RECRUITING·A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Conditions: Untreated Melanoma · Unresectable Melanoma · Metastatic Melanoma·Matched via name phrase
- NCT06066138·RECRUITING·A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Conditions: Locally Advanced Alveolar Soft Part Sarcoma · Metastatic Alveolar Soft Part Sarcoma · Locally Advanced Non Small Cell Lung Cancer · Metastatic Non Small Cell Lung Cancer·Matched via name phrase
- NCT04119024·RECRUITING·Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Conditions: Metastatic Malignant Solid Neoplasm · Metastatic Melanoma · Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 · Pathologic Stage IV Cutaneous Melanoma AJCC v8·Matched via name phrase
- NCT06739226·RECRUITING·Combination Immunotherapy Targeting Melanoma
Conditions: Melanoma·Matched via name phrase
- NCT06214156·RECRUITING·A Clinical Study of T3011 in Subjects With Advanced Melanoma
Conditions: Advanced Melanoma·Matched via name phrase
- NCT04282044·RECRUITING·Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Conditions: Solid Tumor, Adult · Triple Negative Breast Cancer · Colorectal Cancer · Hepatocellular Carcinoma·Matched via name phrase
- NCT07581509·NOT YET RECRUITING·Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma
Conditions: Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)·Matched via name phrase
- NCT05704647·RECRUITING·Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
Conditions: Melanoma (Skin)·Matched via name phrase
- NCT07371663·RECRUITING·An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Conditions: Solid Cancers · NSCLC (Advanced Non-small Cell Lung Cancer) · Gastric (Stomach) Cancer · Endometrial Cancer·Matched via name phrase
- NCT06708663·RECRUITING·HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Conditions: Biliary Tract Cancer · Melanoma·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Familial melanoma" OR "hereditary melanoma (disease)"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Familial melanoma" OR "hereditary melanoma (disease)"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"melanoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1514) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T14:35:24.288Z
